Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorPrograma d'Harmonització Farmacoterapèutica
dc.date.accessioned2021-06-22T09:49:01Z
dc.date.available2021-06-22T09:49:01Z
dc.date.issued2021-03-03
dc.identifier.citationPrograma d'Harmonització Farmacoterapèutica. Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu. Barcelona: Servei Català de la Salut; 2021.
dc.identifier.urihttps://hdl.handle.net/11351/6089
dc.descriptionRheumatoid arthritis; Upadacitinib; JAK inhibitor
dc.description.abstractRheumatoid arthritis (RA) is an inflammatory disease of autoimmune etiology characterized by chronic inflammation of the synovial membrane, which leads to the progressive destruction of joint structures. Typical symptoms include pain, swelling, joint stiffness, asthenia, malaise, fever, and weight loss, and tend to functionally limit the affected joints if left untreated. Extraarticular manifestations may appear, such as anorexia, subcutaneous nodules, serositis or vasculitis.
dc.language.isocat
dc.publisherServei Català de la Salut
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectArtritis reumatoide - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectMedicaments - Assaigs clínics
dc.subject.meshArthritis, Rheumatoid
dc.subject.mesh/drug therapy
dc.subject.meshDrug Evaluation
dc.titleUpadacitinib per al tractament de l’artritis reumatoide de moderada a greu
dc.typeinfo:eu-repo/semantics/report
dc.subject.decsartritis reumatoide
dc.subject.decs/farmacoterapia
dc.subject.decsevaluación de medicamentos
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record